Trial Data Presented at BSG Live’25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement ...

Oral Presentations. Students in the oral presentation track will be assigned a presentation session when they must be available to present to a panel of 3 - 5 judges. Presenters will have access to a ...

Oral Presentation. 1. Presentation Title: Efficacy and safety results of a first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein, IBI363, in patients with immunotherapy-treated, ...

At this year's ASCO meeting, three oral presentations of IBI363 reported encouraging Phase 1/2 clinical data in the first three indications explored—NSCLC, CRC, and melanoma—focusing on IO ...

Oral Presentations: The final oral presentation schedule will be available on the website by Friday, July 25, 2025. Scheduling will occur in 15-minute increments, grouped with presentations from the ...

YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a ...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

If I am unable to attend my live oral session, can I pre-record a presentation and have this played during the session? No, all oral presentations must be completed during the live session. If you are ...

PleoPharma, Inc. shared encouraging findings from its Phase 2b clinical trial of PP-01, a novel treatment for Cannabis ...

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

At this year's ASCO meeting, three oral presentations of IBI363 reported encouraging Phase 1/2 clinical data in the first three indications explored—NSCLC, CRC, and melanoma—focusing on IO ...